Literature DB >> 11572743

Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models.

W A Ghali1, H Quan, R Brant, G van Melle, C M Norris, P D Faris, P D Galbraith, M L Knudtson.   

Abstract

CONTEXT: Adjusted survival curves are often presented in medical research articles. The most commonly used method for calculating such curves is the mean of covariates method, in which average values of covariates are entered into a proportional hazards regression equation. Use of this method is widespread despite published concerns regarding the validity of resulting curves.
OBJECTIVE: To compare the mean of covariates method to the less widely used corrected group prognosis method in an analysis evaluating survival in patients with and without diabetes. In the latter method, a survival curve is calculated for each level of covariates, after which an average survival curve is calculated as a weighted average of the survival curves for each level of covariates. DESIGN, SETTING, AND PATIENTS: Analysis of cohort study data from 11 468 Alberta residents undergoing cardiac catheterization between January 1, 1995, and December 31, 1996. MAIN OUTCOME MEASURES: Crude and risk-adjusted survival for up to 3 years after cardiac catheterization in patients with vs without diabetes, analyzed by the mean of covariates method vs the corrected group prognosis method.
RESULTS: According to the mean of covariates method, adjusted survival at 1044 days was 94.1% and 94.9% for patients with and without diabetes, respectively, with misleading adjusted survival curves that fell above the unadjusted curves. With the corrected group prognosis method, the corresponding survival values were 91.3% and 92.4%, with curves that fell more appropriately between the unadjusted curves.
CONCLUSIONS: Misleading adjusted survival curves resulted from using the mean of covariates method of analysis for our data. We recommend using the corrected group prognosis method for calculating risk-adjusted curves.

Entities:  

Mesh:

Year:  2001        PMID: 11572743     DOI: 10.1001/jama.286.12.1494

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  74 in total

1.  Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans.

Authors:  Lesley A Anderson; Steven C Moore; Gloria Gridley; B J Stone; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-01-27

2.  Invasive cardiac procedure use and mortality among South Asian and Chinese Canadians with coronary artery disease.

Authors:  Hude Quan; Nadia Khan; Bing Li; Karin H Humphries; Peter Faris; P Diane Galbraith; Michelle Graham; Merril L Knudtson; William A Ghali
Journal:  Can J Cardiol       Date:  2010 Aug-Sep       Impact factor: 5.223

3.  Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training.

Authors:  Ann M Swank; John Horton; Jerome L Fleg; Gregg C Fonarow; Steven Keteyian; Lee Goldberg; Gene Wolfel; Eileen M Handberg; Dan Bensimhon; Marie-Christine Illiou; Marianne Vest; Greg Ewald; Gordon Blackburn; Eric Leifer; Lawton Cooper; William E Kraus
Journal:  Circ Heart Fail       Date:  2012-07-06       Impact factor: 8.790

4.  Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.

Authors:  Yoshikuni Kawaguchi; Scott Kopetz; Timothy E Newhook; Mario De Bellis; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Clin Cancer Res       Date:  2019-06-20       Impact factor: 12.531

5.  Should patients perception of health status be integrated in the prognostic assessment of heart failure patients? A prospective study.

Authors:  Paola Di Giulio
Journal:  Qual Life Res       Date:  2013-08-04       Impact factor: 4.147

6.  Mortality Rates Among Substance Use Disorder Participants in Clinical Trials: Pooled Analysis of Twenty-Two Clinical Trials Within the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Robert Lindblad; Lian Hu; Neal Oden; Paul Wakim; Carmen Rosa; Paul VanVeldhuisen
Journal:  J Subst Abuse Treat       Date:  2016-08-15

7.  Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension.

Authors:  Wen-Hui Wu; Lu Yang; Fu-Hua Peng; Jing Yao; Li-Ling Zou; Dong Liu; Xin Jiang; Jue Li; Lan Gao; Jie-Ming Qu; Steven M Kawut; Zhi-Cheng Jing
Journal:  Am J Respir Crit Care Med       Date:  2012-12-06       Impact factor: 21.405

8.  Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial.

Authors:  Rober C Welsh; Luc Sauriol; Zugui Zhang; Paul Kolm; Willian S Weintraub; Pierre Theroux
Journal:  Can J Cardiol       Date:  2009-12       Impact factor: 5.223

9.  Past body mass index and risk of mortality among women.

Authors:  S C Moore; S T Mayne; B I Graubard; A Schatzkin; D Albanes; C Schairer; R N Hoover; M F Leitzmann
Journal:  Int J Obes (Lond)       Date:  2008-01-22       Impact factor: 5.095

10.  Prediagnosis soy food consumption and lung cancer survival in women.

Authors:  Gong Yang; Xiao-Ou Shu; Hong-Lan Li; Wong-Ho Chow; Wanqing Wen; Yong-Bing Xiang; Xianglan Zhang; Hui Cai; Bu-Tian Ji; Yu-Tang Gao; Wei Zheng
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.